Rockefeller Capital Management
ACRS icon

Rockefeller Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Rockefeller Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.9K Buy
6,112
+4,886
+399% +$16.5K ﹤0.01% 3655
2025
Q4 		$3.69K Buy
+1,226
New +$3.1K ﹤0.01% 4159
2020
Q2 		– Sell
-1,000
Closed -$1K – 2565
2020
Q1 		$1K Buy
+1,000
New +$1.36K ﹤0.01% 2247

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rockefeller Capital Management's ACRS Position: Q1 2026 in Review

Rockefeller Capital Management increased its Aclaris Therapeutics (ACRS) stake by 399% in Q1 2026, buying an estimated $16.5K and bringing the position to 6,112 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Rockefeller Capital Management first reported a position in ACRS in Q1 2020 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Rockefeller Capital Management held 6,112 shares of Aclaris Therapeutics worth $22.9K as of Q1 2026.
  • Rockefeller Capital Management bought 4,886 Aclaris Therapeutics shares in Q1 2026, an estimated $16.5K.
  • Aclaris Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3655 holding.
  • Rockefeller Capital Management first reported a position in Aclaris Therapeutics in Q1 2020 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.